CDK12 Amplification

CI-VAR-00000258Explore in graph →CIViC 5250

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Breast Neoplasm1
ERBB2 Amplification AND CDK12 Amplification	Disitamab Vedotin + Trastuzumab Deruxtecan Regimen + Trastuzumab Emtansine RegimenSubstitutes	Predictive	B	Supports Sensitivity Response	3	submitted	EID12569 In a real-world cohort of metastatic breast cancer (n = 63; 30 HER2-positive, 33 HER2-low), patients received HER2-targeted antibody-drug conjugates (trastuzumab deruxtecan (68.25%), disitamab vedotin… (full text at CIViC) PMID 39806366 · Huang et al., 2025 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.